Short Interest in FocalTherics (NASDAQ:FOCL) Increases By 140.7%

FocalTherics (NASDAQ:FOCL) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 134,939 shares, a growth of 140.7% from the May 31st total of 56,059 shares. Based on an average daily volume of 40,322 shares, the days-to-cover ratio is presently 3.3 days. Currently, 0.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Insider Buying and Selling

In other FocalTherics news, Director Joshua Levine acquired 10,000 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $4.22 per share, with a total value of $42,200.00. Following the purchase, the director directly owned 35,000 shares of the company’s stock, valued at approximately $147,700. This represents a 40.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of FOCL. Financial Planning Navigators CORP purchased a new stake in shares of FocalTherics in the fourth quarter worth approximately $33,000. SmartHarvest Portfolios LLC purchased a new position in FocalTherics during the 1st quarter valued at $38,000. Lido Advisors LLC bought a new position in FocalTherics in the 1st quarter valued at $40,000. Kovack Advisors Inc. purchased a new stake in FocalTherics in the fourth quarter worth $53,000. Finally, Leonteq Securities AG purchased a new stake in FocalTherics in the fourth quarter worth $313,000. Institutional investors own 62.74% of the company’s stock.

FocalTherics Trading Up 0.8%

Shares of FOCL traded up $0.04 during midday trading on Tuesday, hitting $5.18. The stock had a trading volume of 22,158 shares, compared to its average volume of 52,829. FocalTherics has a 1 year low of $1.21 and a 1 year high of $5.24. The company has a market cap of $194.16 million and a P/E ratio of -6.39. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $20.48 million for the quarter, compared to analysts’ expectations of $19.46 million. FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%. As a group, analysts expect that FocalTherics will post -0.78 EPS for the current year.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.